@entity1955 replacement in primary XXXX : the higher the initial dose the higher the rate of overtreatment.

@entity1 @entity16490 @entity1955 @entity2016 @entity6750 @entity4903
BACKGROUND: @entity6750 ( @entity6750 ) is the most frequent @entity4903 during the neonatal period, and a delay in diagnosis and treatment leads to irreversible complications. A high @entity1955 ( @entity2016 ) dose is recommended for treatment, while the optimal starting dose is still a matter of debate. The objective of this study was to determine the effects of various starting doses of @entity2016 on serum thyroid stimulating hormone (TSH) and @entity1955 (fT4) at the end of the first month of treatment. METHODS: A total of 71 @entity1 (37 males, 52.1%) with @entity6750 were included in the study. The @entity1 were designated into three sets of subgroups according to the following categorical variables: (i) initial @entity2016 doses: 6-9.9  g/kg/day, 10-11.9  g/kg/day and 12-17  g/kg/day; (ii) initial TSH levels: 6-9.99  IU/mL, 10-75  IU/mL and >75  IU/mL; and (iii) etiology: dyshormonogenesis and @entity16490 . A fT4 level >2.3 ng/dL  a TSH level <0.5  IU/mL were considered as overtreatment. RESULTS: The mean age of the study population was 22.3  13.2 days at diagnosis. At diagnosis, the mean fT4 was 0.84  0.32 ng/dL, and TSH was 39.3  30  IU/mL. The mean initial dose of @entity2016 was 10.9  2.9  g/kg/day. Overtreatment rates were significantly higher in the highest dose group (12-17  g/kg/day) compared with the lowest dose group (6-9.9  g/kg/day) (61.5% and 25%, respectively, p<0.05). None of the @entity1 was undertreated. CONCLUSIONS: In this study, we found that the rate of overtreatment was significantly higher in @entity1 who were given @entity2016 doses of 12-17  g/kg/day. Thus, monitoring thyroid functions earlier than one month of treatment is necessary.
